Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02978859 · ClinicalTrials.gov registry record · Phase 2
Sitravatinib in Advanced Liposarcoma and Other Soft Tissue Sarcomas
A Phase 2 study, sponsored by Columbia University.
- Completed
- Registry status
- Phase 2
- Development phase
- 29
- Enrollment target
NCT02978859 is a Phase 2 study that has completed, run by Columbia University. The registered enrollment target is 29 participants.
The verdict
NCT02978859, a Phase 2 study, has completed, sponsored by Columbia University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 29 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate Sitravatinib, an oral small molecular receptor tyrosine kinase inhibitor, for the treatment of advanced liposarcoma.
Interventions
- DRUG MGCD516
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 29 participants |
| Start Date | 2016-11 |
| Est. Completion | 2021-12-20 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02978859
The ClinicalTrials.gov registry entry for NCT02978859 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 29 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Columbia University, which has 958 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which MGCD516 is the first listed.
NCT02978859 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02978859 about?
NCT02978859 is a clinical study titled "Sitravatinib in Advanced Liposarcoma and Other Soft Tissue Sarcomas". The purpose of this study is to evaluate Sitravatinib, an oral small molecular receptor tyrosine kinase inhibitor, for the treatment of advanced liposarcoma.
What is the current status of trial NCT02978859?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 29 participants. The study started on 2016-11. Estimated completion is 2021-12-20.
What interventions are being tested in trial NCT02978859?
The interventions under investigation include: MGCD516 (DRUG).
Who is sponsoring clinical trial NCT02978859?
This trial is sponsored by Columbia University, which has 958 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.